BACKGROUND: Glycemic exposure activates 12-lipoxygenase (12LO) expression and formation of arachidonic acid-derived products. These products can induce cell hypertrophy, cell proliferation, and extracellular matrix deposition, potentially leading to diabetic nephropathy. STUDY DESIGN: Cross-sectional study. SETTINGS & PARTICIPANTS: 955 European-American siblings from 369 Diabetes Heart Study families. Participants were categorized as nondiabetic, diabetic with hemoglobin A(1c) level less than 6.5%, and diabetic with hemoglobin A(1c) level greater than 6.5% (uncontrolled type 2 diabetes mellitus). PREDICTOR: Four haplotype-tagging variants in the arachidonate 12LO gene (ALOX12), glycemic control, and other covariates. OUTCOMES & MEASUREMENTS: Albuminuria measured by means of urinary albumin-creatinine ratio (ACR). RESULTS: Median ACR was 11.9 mg/g (interquartile range, 5.6 to 39.1). The overall test of the Arg261Gln genotypic association with ACR was significant (P = 0.009). Compared with 261Arg allele carriers, adjusted mean ACR was 42% greater in the 189 carriers of two 261Gln alleles (95% confidence interval, 10 to 83; P = 0.007). This association was confined to the group with uncontrolled type 2 diabetes mellitus (N = 623) with the greatest ACRs (P < 0.001). Adjustments for additional determinants of ACR yielded similar results. LIMITATIONS: Urine ACR was measured in duplicate on only a single occasion. This study was limited to European Americans. CONCLUSIONS: Consistent with animal and cellular studies, these results provide additional evidence of the importance of the 12LO pathway in the pathogenesis of human diabetic nephropathy.
BACKGROUND: Glycemic exposure activates 12-lipoxygenase (12LO) expression and formation of arachidonic acid-derived products. These products can induce cell hypertrophy, cell proliferation, and extracellular matrix deposition, potentially leading to diabetic nephropathy. STUDY DESIGN: Cross-sectional study. SETTINGS & PARTICIPANTS: 955 European-American siblings from 369 Diabetes Heart Study families. Participants were categorized as nondiabetic, diabetic with hemoglobin A(1c) level less than 6.5%, and diabetic with hemoglobin A(1c) level greater than 6.5% (uncontrolled type 2 diabetes mellitus). PREDICTOR: Four haplotype-tagging variants in the arachidonate 12LO gene (ALOX12), glycemic control, and other covariates. OUTCOMES & MEASUREMENTS: Albuminuria measured by means of urinary albumin-creatinine ratio (ACR). RESULTS: Median ACR was 11.9 mg/g (interquartile range, 5.6 to 39.1). The overall test of the Arg261Gln genotypic association with ACR was significant (P = 0.009). Compared with 261Arg allele carriers, adjusted mean ACR was 42% greater in the 189 carriers of two 261Gln alleles (95% confidence interval, 10 to 83; P = 0.007). This association was confined to the group with uncontrolled type 2 diabetes mellitus (N = 623) with the greatest ACRs (P < 0.001). Adjustments for additional determinants of ACR yielded similar results. LIMITATIONS: Urine ACR was measured in duplicate on only a single occasion. This study was limited to European Americans. CONCLUSIONS: Consistent with animal and cellular studies, these results provide additional evidence of the importance of the 12LO pathway in the pathogenesis of humandiabetic nephropathy.
Authors: Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler Journal: Science Date: 2002-05-23 Impact factor: 47.728
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: Marpadga A Reddy; Sharon G Adler; Young-Sook Kim; Linda Lanting; John Rossi; Shin-Wook Kang; Jerry L Nadler; Asha Shahed; Rama Natarajan Journal: Am J Physiol Renal Physiol Date: 2002-11
Authors: Cintia Fridman; Elida P B Ojopi; Sheila P Gregório; Elisa H Ikenaga; Doris H Moreno; Frederico N Demetrio; Pedro E M Guimarães; Homero P Vallada; Wagner F Gattaz; Emmanuel Dias Neto Journal: Eur Arch Psychiatry Clin Neurosci Date: 2003-02 Impact factor: 5.270
Authors: Bruce A Perkins; Linda H Ficociello; Kristen H Silva; Dianne M Finkelstein; James H Warram; Andrzej S Krolewski Journal: N Engl J Med Date: 2003-06-05 Impact factor: 91.245
Authors: Christopher S Carlson; Michael A Eberle; Mark J Rieder; Joshua D Smith; Leonid Kruglyak; Deborah A Nickerson Journal: Nat Genet Date: 2003-03-24 Impact factor: 38.330
Authors: Daniel S Kim; Amber A Burt; David R Crosslin; Peggy D Robertson; Jane E Ranchalis; Edward J Boyko; Deborah A Nickerson; Clement E Furlong; Gail P Jarvik Journal: J Lipid Res Date: 2012-11-15 Impact factor: 5.922
Authors: T Harsløf; L B Husted; M Nyegaard; M Carstens; L Stenkjær; K Brixen; P Eiken; J-E B Jensen; A D Børglum; L Mosekilde; L Rejnmark; B L Langdahl Journal: Osteoporos Int Date: 2010-11-23 Impact factor: 4.507
Authors: Donald W Bowden; Amanda J Cox; Barry I Freedman; Christina E Hugenschimdt; Lynne E Wagenknecht; David Herrington; Subhashish Agarwal; Thomas C Register; Joseph A Maldjian; Maggie C-Y Ng; Fang-Chi Hsu; Carl D Langefeld; Jeff D Williamson; J Jeffrey Carr Journal: Rev Diabet Stud Date: 2010-11-10
Authors: M Luiza Caramori; Youngki Kim; Jason H Moore; Stephen S Rich; Josyf C Mychaleckyj; Nobuaki Kikyo; Michael Mauer Journal: Diabetes Date: 2012-02-07 Impact factor: 9.461